Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Study of Bevacizumab Injection Directly Inside the Keloid Tissue

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical Diagnosis of a flat keloid.~2. Age 18 to 50~3. A signed informed consent document (ICD)~4. Able and willing to receive bevacizumab~Women of child-bearing potential must have a negative pregnancy test during screening. The effects of bevacizumab on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.~Exclusion Criteria:~1. Pedunculated Keloid~2. Diastolic Blood pressure of 90 mm Hg or above~3. History of any degree of Hypertension, even medically controlled hypertension~4. History of any form of cardiovascular disease or stroke~5. History of any form of thromboembolic event~6. History of renal dysfunction or proteinuria~7. History of recent (past 12 month) or planned (next 3 months) major surgery,~8. Men and women who plan to have children within 6 months of their last treatment~9. Psychological Illness that may result in non compliance with treatment~10. Pregnancy and Breast Feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- bevacizumab for all patients (Type: EXPERIMENTAL): This is a single arm trial. All patients receive treatment with bevacizumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).